We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Memory Pharmaceuticals is currently conducting a safety and tolerability study
in Alzheimer's patients of MEM 1003, a neuronal L-type calcium channel modulator.
At the 10th International Myeloma Workshop, James Berenson, medical and scientific
director of the Institute for Myeloma and Bone Cancer Research presented data
from a multicenter, Phase II trial of a Trisenox combination regimen, known
as MAC (melphalan, Trisenox and vitamin C), in relapsed or refractory multiple
myeloma patients.
Alexion Pharmaceuticals has completed enrollment of the pivotal Phase III TRIUMPH
efficacy trial of eculizumab in patients with the chronic orphan blood disorder
Paroxysmal Nocturnal Hemoglobinuria (PNH).
Celgene has announced initial clinical results from its pivotal Phase III special
protocol assessment (SPA) trials using Revlimid (lenalidomide) as a new approach
in the treatment of heavily pretreated patients with relapsed or refractory
multiple myeloma.
Array BioPharma has announced an expansion of a collaboration agreement with
Genentech to develop small molecule drugs against an additional protein target
in the field of oncology.
Neurochem has unblinded the Phase II/III clinical study for its investigational
product candidate, 1,3-propanedisulfonate (1,3PDS; Fibrillex) to treat Amyloid
A amyloidosis.
Cardiome Pharma has released final results for the physician-sponsored "EXOTIC-EF"
clinical study for oxypurinol in congestive heart failure (CHF) patients.